Editas Medicine to Present at Upcoming February In
Post# of 301275
CAMBRIDGE, Mass., Feb. 10, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT ), a leading genome editing company, today announced that management will present a company overview at two upcoming investor conferences in February. Details of the presentations are as follows:
| 19 th Annual BIO CEO & Investor Conference | |
| Date: | Monday, February 13, 2017 |
| Time: | 3:00 p.m. ET |
| Location: | New York City |
| RBC Capital Markets 2017 Global Healthcare Conference | |
| Date: | Wednesday, February 22, 2017 |
| Time: | 10:30 a.m. ET |
| Location: | New York City |
Live webcasts of the presentations will be available on the Investors & Media section of the Editas website at www.editasmedicine.com . Archived replays will be available for approximately 30 days following the respective presentations.
About Editas Medicine Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 dan@purecommunicationsinc.com Investor Contact Mark Mullikin Editas Medicine, Inc. (617) 401-9083 mark.mullikin@editasmed.com
(0)
(0)